- Legally competent patients who are personally capable of giving informed consent and to sign and date the Consent Form prior to any trial related activity,- Patients aged from 50 to 80 years, whether vaccinated to SARS-CoV-2 or not. Unvaccinated patients can be included only if they do not fulfil the following risk factors for a severe course of SARS-CoV-2 infection: Diabetes, obesity (BMI > 25), chronic lung disease (including asthma), chronic kidney disorder, current smoking, immunosuppressive disease or immunosuppressive therapy, heart disease,hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medical technological dependence, or age 60 years or older, regardless of comorbidities. The patient’s family physician will take the decision on the inclusion of unvaccinated patients, considering the patient’s anamnesis and concomitant medication.- Having the diagnosis of SARS-CoV-2 infection documented by a positive Rapid Antigen Test or positive PCR testing. Positive Rapid Antigen Test results must be confirmed through another Rapid Antigen test performed in presence of the investigator during the inclusion visit. Patients will be included in the study based on eligibility criteria and after signing the informed consent. The patient will undergo allstudy related procedures on the same day (baseline RT-PCR test using nasal swabs, physical examination, vital signs, concomitant medications etc) including study drug administration. The decision of continuing the patient further in the study will be decided on the results of RT-PCR (patients exhibiting baseline Ct-values = 25 will be continued, patients exhibiting baseline Ct-values > 25 will be discontinued from the study). In case of baseline Ct-values > 25, the drug will be immediately withdrawn, and patients will be discontinued from the study.

- Legally competent patients who are personally capable of giving informed consent and to sign and date the Consent Form prior to any trial related activity,- Patients aged from 50 to 80 years, whether vaccinated to SARS-CoV-2 or not. Unvaccinated patients can be included only if they do not fulfil the following risk factors for a severe course of SARS-CoV-2 infection: Diabetes, obesity (BMI > 25), chronic lung disease (including asthma), chronic kidney disorder, current smoking, immunosuppressive disease or immunosuppressive therapy, heart disease,hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medical technological dependence, or age 60 years or older, regardless of comorbidities. The patient’s family physician will take the decision on the inclusion of unvaccinated patients, considering the patient’s anamnesis and concomitant medication.- Having the diagnosis of SARS-CoV-2 infection documented by a positive Rapid Antigen Test or positive PCR testing. Positive Rapid Antigen Test results must be confirmed through another Rapid Antigen test performed in presence of the investigator during the inclusion visit. Patients will be included in the study based on eligibility criteria and after signing the informed consent. The patient will undergo allstudy related procedures on the same day (baseline RT-PCR test using nasal swabs, physical examination, vital signs, concomitant medications etc) including study drug administration. The decision of continuing the patient further in the study will be decided on the results of RT-PCR (patients exhibiting baseline Ct-values = 25 will be continued, patients exhibiting baseline Ct-values > 25 will be discontinued from the study). In case of baseline Ct-values > 25, the drug will be immediately withdrawn, and patients will be discontinued from the study.